Myriad
Myriad Genetics, Memorial Sloan Kettering Partner to Study MRD Testing in Breast Cancer
The collaborators will evaluate the use of Myriad's MRD platform in predicting response to CDK4/6 inhibitors and in a chemotherapy neoadjuvant setting.
Myriad Genetics, Onsite Women's Health Partner to ID Women With High Breast Cancer Risk
The program makes Myriad's hereditary breast cancer and risk assessment tools available to Onsite's pool of over 400,000 patients.
Myriad Genetics to Settle Shareholder Lawsuit for $77.5M; Q2 Revenues Grow 2 Percent
The molecular diagnostics firm saw 38 percent growth in testing volume in Q2 but missed the Wall Street revenue consensus as it lost $116.1 million.
Myriad Genetics Enters $90M Asset-Based Credit Agreement
The credit facility includes an option to increase the maximum principal amount by $25 million and matures on June 30, 2026.
Myriad Genetics Revenues Grow 10 Percent, Beating Wall Street Estimate
Strong test volume growth drove the revenue increase, while net loss more than doubled year over year.
Apr 3, 2023
Apr 3, 2023
360Dx Top 30 Rebounds 2 Percent in March
Feb 1, 2023
360Dx Top 30 Starts the Year up 1 Percent
Nov 2, 2022
Nov 1, 2022
Oct 20, 2022
Aug 5, 2022
Aug 1, 2022